The low volume of plasma and few genome copies available in liquid biopsy assays limits the detection of variants at low allele frequencies, potentially causing false-negative results. Additionally, the fraction of cell-free DNA varies between cancer types, with circulating tumor DNA sometimes being as low as 0.1 percent of total DNA in a sample. Moreover, clonal hematopoiesis and errors introduced during library preparation can cause false-positive results.
This webinar from LGC Clinical Diagnostics presents data demonstrating the utility of circulating tumor DNA reference materials in supporting the validation and standardization of liquid biopsy assays and in pushing the limit of detection and the sensitivity of such tests.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences